Ruchika Chitravanshi And Sohini Das

Stories by Ruchika Chitravanshi And Sohini Das

Early signs of COVID-19 surge cooling in 13 states and Union Territories

Early signs of COVID-19 surge cooling in 13 states and Union Territories

Rediff.com   4 May 2021

But the numbers have continued to rise in 23 states including Bihar, Goa, Andhra Pradesh, Tamil Nadu and Kerala.

Covid vaccine: Too early to say if booster dose needed

Covid vaccine: Too early to say if booster dose needed

Rediff.com   30 Apr 2021

Initial data has shown immunity triggered by the two mRNA vaccines -- Pfizer-BioNTech and Moderna -- lasts for at least six months

Covid vaccine could cost up to Rs 1000 in private market

Covid vaccine could cost up to Rs 1000 in private market

Rediff.com   28 Apr 2021

While the Indian government has been procuring Covid-19 vaccines at low prices so far, manufacturers have to declare the prices of vaccines they would supply to the open market (industries, private hospitals, etc) and state governments before May 1. Sohini Das reports.

A COVID-19 Vaccine Snapshot

A COVID-19 Vaccine Snapshot

Rediff.com   28 Apr 2021

Sputnik V is already approved in India and Sinovac is unlikely to come in as it does not meet the criteria.

Where is the manpower to handle ventilators?

Where is the manpower to handle ventilators?

Rediff.com   25 Apr 2021

The second wave of the pandemic has not only crippled medical infrastructure in terms of hospital beds, but has also led to bottlenecks in invasive ventilators and medical oxygen capacities and supplies.

Demand for Covid-19 tests growing 100 pc week-on-week

Demand for Covid-19 tests growing 100 pc week-on-week

Rediff.com   23 Apr 2021

One challenge for many laboratories in ramping up is the shortage of trained manpower for collecting samples, report Sohini Das, Vinay Umarji and Virendra Singh Rawat.

Shortage of key chemical from US hits Covaxin ramp-up plans

Shortage of key chemical from US hits Covaxin ramp-up plans

Rediff.com   22 Apr 2021

'In case of shortage of other raw material, like filters and bags, one can try to develop another vendor. However, for chemicals as critical as adjuvants, this is not possible'

Serum, Bharat Biotech to get Rs 45 bn for 300 mn vaccines

Serum, Bharat Biotech to get Rs 45 bn for 300 mn vaccines

Rediff.com   20 Apr 2021

This will be an upfront payment for the vaccine doses that these two companies will supply to the government.

COVID-19 vaccine: Why Poonawalla wrote to Biden

COVID-19 vaccine: Why Poonawalla wrote to Biden

Rediff.com   17 Apr 2021

'The US has invoked the Defence Act and banned export of raw materials.' 'This is as good as banning vaccines.'

100 million Covaxin vaccines by Sept

100 million Covaxin vaccines by Sept

Rediff.com   17 Apr 2021

The production of Covaxin will increase from the current 10 million doses per month to 60 million-70 million by July-August.

Second Covid wave is 1.7x times faster than first wave, shows data

Second Covid wave is 1.7x times faster than first wave, shows data

Rediff.com   15 Apr 2021

It has taken 51 days to reach a daily caseload of 84,000 from 11,000, as against 85 days taken in the first wave, report Abhishek Waghmare and Sohini Das.

'We will be prioritising vaccine only for India'

'We will be prioritising vaccine only for India'

Rediff.com   14 Apr 2021

'I don't think anybody would want to be in my position today where every head of State has to be explained that I am prioritising my country because there is a surge in cases.'

Serum, Bharat Bio seek govt funds to boost vaccine output

Serum, Bharat Bio seek govt funds to boost vaccine output

Rediff.com   5 Apr 2021

Both manufacturers have sought funds in excess of Rs 150 crore under the department of biotechnology's Mission Covid Suraksha scheme. Announced last November, the scheme has an outlay of Rs 900 crore to help develop Covid vaccines, from the clinical development stage to setting up production sites.

Expert panel seeks more data on Sputnik V Covid vaccine

Expert panel seeks more data on Sputnik V Covid vaccine

Rediff.com   2 Apr 2021

'No approval was given to Sputnik V on Thursday. Some queries have been asked on safety, efficacy, and logistics, which the firm will have answers to at the next meeting'

Sputnik V vaccine may be added to India's Covid armoury soon

Sputnik V vaccine may be added to India's Covid armoury soon

Rediff.com   30 Mar 2021

'We expect to get the approval in the next few weeks,' says Deepak Sapra, CEO, API and pharmaceutical services, Dr Reddy's Laboratories (DRL).

IBC: 'Defaulters' paradise is lost'

IBC: 'Defaulters' paradise is lost'

Rediff.com   30 Mar 2021

'The Insolvency and Bankruptcy Code cleans up non-performing assets and puts companies in capable and credible hands.'

Bharat Biotech's Krishna Ella wins Covaxin fight

Bharat Biotech's Krishna Ella wins Covaxin fight

Rediff.com   22 Mar 2021

'He came back from the US only to work for his country.' 'He has invested his fortunes to build this company and is married to his work.' 'Rarely does one see such commitment.'

Independent directors of loss-making firms must be paid: Govt

Independent directors of loss-making firms must be paid: Govt

Rediff.com   20 Mar 2021

Till now, there was no provision in the Companies Act that allowed a remuneration for the non-executive director if the company was in loss or had inadequate profits. Only the executive director was entitled for a remuneration in the event of a loss.

Whistleblower accuses Edelweiss ARC of fund diversion, other irregularities

Whistleblower accuses Edelweiss ARC of fund diversion, other irregularities

Rediff.com   20 Mar 2021

The ministry of corporate affairs (MCA) has launched a probe into the books of Edelweiss Asset Reconstruction Company (EARC) following allegations by a whistleblower of fund diversion and irregularities. The whistleblower, Paras Kuhad, a former additional solicitor general of India, had written to the Prime Minister's Office and the Reserve Bank of India (RBI). Kuhad has alleged that Edelweiss Group and Caisse de depot et placement du Qubec (CDPQ), a Canadian institutional investor, which hold stakes in the ARC, diverted funds and did not adhere to norms while making investments in EARC's instruments. Sources have indicated that a probe has been initiated, but the MCA did not comment on the issue.

Stressed firms must get ready for bankruptcy proceedings

Stressed firms must get ready for bankruptcy proceedings

Rediff.com   18 Mar 2021

With just a few days left for the suspension on fresh corporate insolvency cases to end, government sources have indicated that another extension is unlikely. An extension may not be economically desirable as it hampers the restructuring prospects for stressed companies, according to senior officials. Also, it would be a challenge to amend the law in such a short time. A Bill would have to be passed in both Houses of Parliament, if any change, with respect to suspension of Insolvency and Bankruptcy Code (IBC), is to be made - including extension or creating any exceptions to the rule.